TCGA-CR-6488-01A-12R-2081-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.550
- ANGIOGENESIS+0.510
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.420
- KRAS_SIGNALING_UP+0.350
- TGF_BETA_SIGNALING+0.340
- UV_RESPONSE_DN+0.340
- COAGULATION+0.320
- APICAL_JUNCTION+0.300
- KRAS_SIGNALING_DN+0.240
- APICAL_SURFACE+0.230
Top 10 suppressed
- MYC_TARGETS_V2-0.680
- MYC_TARGETS_V1-0.670
- E2F_TARGETS-0.610
- OXIDATIVE_PHOSPHORYLATION-0.590
- G2M_CHECKPOINT-0.490
- UNFOLDED_PROTEIN_RESPONSE-0.480
- MTORC1_SIGNALING-0.470
- INTERFERON_ALPHA_RESPONSE-0.450
- DNA_REPAIR-0.390
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BB-8596-01A-11R-2403-07 | — | — | 0.929 |
| 2 | TCGA-SY-A9G0-01A-12R-A38B-07 | — | — | 0.922 |
| 3 | TCGA-E2-A1IO-01A-11R-A144-07 | — | A | 0.920 |
| 4 | TCGA-DK-A3IQ-01A-31R-A32Y-07 | — | — | 0.914 |
| 5 | 6b32f047-89ca-40e7-950f-a03493ea90c7 | — | — | 0.914 |
| 6 | TCGA-MP-A4T9-01A-11R-A24X-07 | — | cohortA1 | 0.913 |
| 7 | 4108a871-c064-4537-9331-e59798d7d492 | — | — | 0.913 |
| 8 | TCGA-EW-A1IX-01A-12R-A144-07 | — | A | 0.907 |
| 9 | SRR11296795 | — | — | 0.905 |
| 10 | C3N-02193 | — | cohortA1 | 0.905 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.550 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.510 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.420 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.240 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.110 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |